OUHSC Research News – Monday, July 11, 2022

 

Notices and Reminders

SoonerTrack II Go-Live Announcement

The Office of Research Administration (ORA) is pleased to announce that the SoonerTrack II system is now live! This new system has replaced the SoonerTrack I system used to route grant applications and agreements. The launch webpage for the system is https://fs.ou.edu. User guides and training materials are available at https://research.ouhsc.edu/Research-Administration/SoonerTrack-II-Support. If you have any questions, please contact soonertrackhelpdesk@ouhsc.edu.

** Please be aware that beginning July 11, all SoonerTrack tickets in Pre-Submission status (tickets that have not yet reached ORA) MUST be resubmitted through the new SoonerTrack.

 

SoonerTrack II Training Opportunities

Pre-scheduled SoonerTrack II training sessions are available at the following dates and times. All sessions are the same, so register for the one that best fits your schedule. Additional dates will be provided as needed (These sessions will be conducted via Zoom).  

1. Wednesday, Jul 13, 2022, 10:30 AM - 11:30 AM

Register here

2. Wednesday, Jul 20, 2022, 1:30 PM - 2:30 PM

Register here

 

The Office of Vice President for Research (OVPR) and the Office of Research Administration (ORA) at the OU Health Sciences Center Announcing the Launch of the Newly Redesigned Website

We are excited to announce the launch of our newly redesigned website. The new design allows for streamlined menus and clear navigation, and offers quick and easy access to essential information for our faculty and staff. Explore the website at https://research.ouhsc.edu. We welcome your feedback. Please send any questions or comments to oradmin@ouhsc.edu.

 

OUHSC Funding Opportunities

Presbyterian Health Foundation (PHF) Bridge Grant Program – Request For Applications

• Cycle II PHF Bridge Grant Program Deadline: July 29, 2022

The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications  and provides critiques. 

IMPORTANT UPDATE: This program can now provide funding for up to $100,000 for one year. SALARY and FRINGE BENEFITS may be requested for the Principal Investigator(s) up to $25,000 in total (salary + fringe benefits = $25,000) with the remaining portion, $75,000, used to support the project costs. Guidelines and Application Form are attached or can be found here.  If you have any questions, please email  VPR@ouhsc.edu

 

The Presbyterian Health Foundation and the Oklahoma Center for Therapeutic Sciences 2022 pilot award

The Presbyterian Health Foundation (PHF) and the Oklahoma Center for Therapeutic Sciences (CTS) are soliciting proposals for Investigator Seed Grant Awards in drug and probe discovery. The current RFA is focused on funding pilot projects that utilize the Drug and Target Discovery (DTD) High Throughput Screening (HTS) Facility and the Laboratory of Molecular Structure and Function (MSF). DTD can perform screens of its 7 chemical libraries (~100,000 compounds) using cell-based high-content imaging, as well as fluorescence, fluorescence polarization, TR-FRET, absorbance, and luminescence of cell-based assays or assays using purified components. DTD has cell culture facilities and a full suite of detection, robotic, and imaging equipment designed to facilitate work in microwell plates (96-or 384-well formats). The Facility will assist investigators in the design and development of screen assays that can use all currently available assay readouts and formats. Funding for pilot projects that utilize MSF will be focused on the use of its structure-guided software tools.

Documents for the pilot award announcement and a brochure describing the capabilities of CTS are attached.

If you have any questions, please contact Matthew Hart, Ph.D. at Matthew-J-Hart@ouhsc.edu

 

Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• Chinook Therapeutics is interested is collaboration to develop therapeutics targeting molecular drivers of kidney disease progression.  Approaches of interest include primary glomerular diseases, autoimmune-related renal disease, rare kidney disease indications, nephrolithiasis, PKD and renal transplant.  Novel genetic targets, drug-repurposing and novel approaches for targeted delivery are of interest.  Out of scope: congenital disease, diabetic nephropathy, acute injury and renal fibrosis.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 07/28)
• Beckley Psytech is looking to collaborate on serotonin receptor agonists with therapeutic potential for neurological and psychiatric disorders.  Compounds with selectivity for 5HT2A are of highest interest, however compounds with additional selectivity for 5HT2B, Sigma 1, 5HT1D and 5HT7 will also be considered as will novel approaches for targeted delivery and compound scaffolds based on tryptamine, ergoline or phenethylamine.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 07/28)

 

 NIH Notices 

• Notice of Change to PAR-21-341, Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
  (NOT-CA-22-105)
• Notice on Informational Webinar on the "Research on Interventions that Promote the Careers of Individuals in the Biomedical Research Enterprise (R01)" Program
  (NOT-GM-22-036)
• Notice of Applicant Information Webinar for the NIGMS Bridges to the Baccalaureate (B2B)(T34) and the Bridges to the Doctorate (B2D)(T32)
  (NOT-GM-22-040)
• Notice of Special Interest (NOSI): Advancing Research on Early Pregnancy Loss
  (NOT-HD-22-026)
• Notice of Availability of Frequently Asked Questions (FAQs) for RFA-HL-23-015 and RFA-HL-23-016 "New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI) (UG3/UH3) (U24)"
  (NOT-HL-22-027)
• Notice of NHLBI Participation in PAR-22-132 "Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low-and Middle-Income Countries and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional)"
  (NOT-HL-22-035)
• NHLBI Announces New Policies Regarding Budget Guidelines for SBIR/STTR Applications
  (NOT-HL-22-036)
• Notice of Information: High Priority Countries for the Center for Global Mental Health Research
  (NOT-MH-22-235)
• Notice of Information on High Priority Research Areas for Sex and Gender Influences on the Adolescent Brain and Mental Health of Girls and Young Women (Ages 12-24)
  (NOT-MH-22-245)
• Notice of Participation of Additional NIH Institutes and Centers in RFA-HG-22-002: Educational Hub for Enhancing Diversity in Computational Genomics and Data Science (U24 Clinical Trials Not Allowed)
  (NOT-OD-22-156)
• Request for Information (RFI) on the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Strategic Plan for Fiscal Years (FYs) 2025-2029
  (NOT-AR-22-023)
• Request for Information: Improving our understanding of the role of diet and other factors in the Developmental Origins of Health and Disease (DOHaD)
  (NOT-OD-22-157)
• Notice of Correction for NOT-CA-22-014 "Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment"
  (NOT-CA-22-102)
• Notice to update Application Due Dates for PAR -18-604 "Vet-LIRN Network Capacity-Building Projects (U18)"
  (NOT-FD-22-014)
• FDA Notice of Special Interest (NOSI) to update NOT-FD-22-006 with new application due dates for COVID-19 Capacity Building Grants for PAR-18-604 Vet-LIRN Network Capacity-Building Projects (U18)
  (NOT-FD-22-016)
• Notice of Change to Application Due Date for RFA-RM-22-016 "Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required)"
  (NOT-RM-22-018)
• Notice of Intent to Publish a Funding Opportunity Announcement for The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
  (NOT-CA-22-112)
• Notice of Intent to Publish a Funding Opportunity Announcement for Transforming NHGRIs Diversity Action Plan (R25 Clinical Trials Not Allowed)
  (NOT-HG-22-023)
• Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed)
  (NOT-MH-22-265)
• Notice of Intent to Publish a Funding Opportunity Announcement for Environmental influences on Child Health Outcomes (ECHO) Measurement Core (U24) Clinical Trial Not Allowed
  (NOT-OD-22-169)
• Notice of Intent to Publish a Funding Opportunity Announcement for Environmental influences on Child Health Outcomes (ECHO) Laboratory Core (U24) Clinical Trial Not Allowed
  (NOT-OD-22-170)
• Notice of Intent to Publish a Funding Opportunity Announcement for Open Competition: Environmental influences on Child Health Outcomes (ECHO) Pregnancy Cohort Study Sites. Clinical Trial Not Allowed (UG3/UH3)
  (NOT-OD-22-171)
• Notice of Intent to Publish a Funding Opportunity Announcement for Environmental influences on Child Health Outcomes (ECHO) Cohort Coordinating Center (U2C) (Clinical Trial Not Allowed)
  (NOT-OD-22-172)
• Notice of Intent to Publish a Funding Opportunity Announcement for Environmental influences on Child Health Outcomes (ECHO) Data Analysis Center (U24) Clinical Trial Not Allowed
  (NOT-OD-22-173)
• Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Pregnancy and Pediatric Cohort Study Sites. Clinical Trial Not Allowed (UG3/UH3)
  (NOT-OD-22-174)
• Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Cohort Study Sites for Pediatric Follow Up. Clinical Trial Not Allowed (UG3/UH3)
  (NOT-OD-22-175)
• Notice of Special Interest: Alzheimers-Focused Administrative Supplements for NIH Grants that are Not Focused on Alzheimers Disease
  (NOT-AG-22-025)
• Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01)
  (NOT-HL-22-030)
  National Heart, Lung, and Blood Institute
• Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes
  (NOT-OD-22-167)

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

 

NIH Funding Opportunities

• Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
  (PAR-22-169)
  Application Receipt Date(s): June 20, 2025
• Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
  (PAR-22-170)
  Application Receipt Date(s): September 07, 2025
• CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
  (PAR-22-209)
  Application Receipt Date(s): October 17, 2024
• Impact of the Microbiome-Gut-Brain Axis on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Not Allowed)
  (PAR-22-211)
  Application Receipt Date(s): October 05, 2022
• Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)
  (PAR-22-213)
  Application Receipt Date(s): September 25, 2025
• Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)
  (RFA-AG-23-017)
  Application Receipt Date(s): October 19, 2022
• NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)
  (RFA-AG-23-029)
  Application Receipt Date(s): February 17, 2023
• NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional)
  (RFA-AG-23-030)
  Application Receipt Date(s): February 17, 2023
• HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Optional)
  (RFA-DA-23-045)
  Application Receipt Date(s): February 02, 2023
• HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional)
  (RFA-DA-23-046)
  Application Receipt Date(s): February 02, 2023
• New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3 - Clinical Trial Not Allowed)
  (RFA-HL-23-015)
  Application Receipt Date(s): October 13, 2022
• New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Coordinating Center (U24 - Clinical Trial Not Allowed)
  (RFA-HL-23-016)
  Application Receipt Date(s): October 13, 2022
• Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
  (RFA-HL-23-017)
  Application Receipt Date(s): October 06, 2022
• Regenerative Medicine Innovation Projects (RMIP) Investigator- Initiated Studies (Collaborative U01 Clinical Trial Not Allowed)
  (RFA-HL-23-019)
  Application Receipt Date(s): October 06, 2022
• Regenerative Medicine Innovation Projects (RMIP) Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)
  (RFA-HL-23-020)
  Application Receipt Date(s): October 06, 2022
• Extracellular RNA Sequencing Research Resource for the Accelerating Medicines Partnership Parkinsons Disease (AMPPD) (R24 - Clinical Trial Not Allowed)
  (RFA-NS-23-014)
  Application Receipt Date(s): September 19, 2022

 

Other Funding Opportunities

Oklahoma Center for Adult Stem Cell Research (OCASCR)

Description: The overall goal of OCASCR is to help adult stem cell and regenerative medicine research thrive in Oklahoma and to serve as a trusted resource for public information on these topics. Grants are accepted for research, equipment, and travel/education, and other areas.

Application Deadline: September 20, 2022

Link to Full Announcement: http://www.ocascr.org/grants/

 

The International Center for Responsible Gaming - Small Grants for Research on Lottery Gambling

Description: The International Center for Responsible Gaming and the Hoosier Lottery are collaborating on a special initiative to encourage research on responsible gambling as it relates to lottery gambling. Research projects may include but are not limited to: 

• Stand-alone research projects or a pilot project; 
• Preliminary research in preparation for a large research project, such as a comprehensive literature review, or instrument development and testing; and 
• Research tasks subsequent to a full research project, such as follow-up testing. 

Applicants may request up to $25,000 in direct costs and $5,000 in Facilities and Administration costs

Application Deadline: September 1, 2022

Link to Full Announcement: https://www.icrg.org/research-center/apply-icrg-funding

 

The Oklahoma Center for the Advancement of Science and Technology (OCAST)  Notice of Funding Opportunity Announcements. OCAST has published a list of Funding Opportunity Announcements for FY 2022. The guidelines for 2022 have not been released yet. Next application submission period opens on August 15, 2022 and closes September 26, 2022. More information about the funding opportunity announcements and additional resources are available here: https://oklahoma.gov/ocast/ogx-overview/funding-opportunities.html.

 

The Cystic Fibrosis Foundation (CFF): Biological Basis for CF-Related Diabetes Program

Description: The intent of this request for applications is to solicit and fund projects that will improve our understanding of the biological basis for the development and progression of cystic fibrosis-related diabetes as well as to identify potential novel therapeutic strategies to manage and treat the disease. 

Application deadline: August 2, 2022

Link to Full Announcement: https://www.cff.org/researchers/biological-basis-cf-related-diabetes-program

 

The Cystic Fibrosis Foundation (CFF): Path to a Cure -- Collaborative Research Grant

Description: Path to a Cure: Collaborative Research Grants are intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat CF, with an emphasis on advancing CFTR gene repair and replacement approaches. Collaborations that bring new investigators and technologies into the CF research community will be given highest priority. Proposals must include preliminary data to justify support from the Cystic Fibrosis Foundation.

Application deadline: July 14, 2022

Link to Full Announcement: https://www.cff.org/researchers/path-cure-collaborative-research-grant

 

DoD FY22 Breast Cancer Research Program (BCRP)

• Breakthrough Award Levels 1 and 2 II (BTA12-2)
• Era of Hope Scholar Award II (EOHS-2)

Pre-Application (Letter of Intent): September 22, 2022
Application: October 6, 2022 

• Breakthrough Award Level 3 II (BTA3-2)
• Breakthrough Award Level 4 II (BTA4-2)
• Innovator Award II (INNOV-2)
• Transformative Breast Cancer Consortium Award II (TBCCA-2)

Pre-Application (Preproposal): August 3, 2022
Invited Application: November 2, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/bcrp

 

DoD FY22 Melanoma Research Program (MRP)

• Melanoma Academy Scholar Award (MASA)
• Mid-Career Accelerator Award (MCAA)
• Team Science Award (TSA)
• Focused Program Award – Rare Melanomas (FPA)

Pre-Application (Letter of Intent): September 14, 2022
Application: October 5, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/mrp

 

DoD FY22 Lupus Research Program (LRP)

• Idea Award (IA)
• Impact Award (IPA)
• Transformative Vision Award (TVA)

Pre-Application (Letter of Intent): August 16, 2022
Application: September 1, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/lrp

 

DoD FY22 Vision Research Program (VRP)

• Clinical Trial Award (CTA)
• Focused Translational Team Science Award (FTTSA)
• Investigator-Initiated Research Award (IIRA)
• Translational Research Award (TRA)

Pre-Application (Preproposal): July 15, 2022
Application: November 9, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/vrp

 

DoD FY22 Rare Cancers Research Program (RCRP)

• Concept Award (CA)
• Idea Development Award (IDA)
• Resource and Community Development Award (RCDA)

Pre-Application (Letter of Intent): July 18, 2022
Application: August 29, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/rcrp

 

DoD FY22 Prostate Cancer Research Program (PCRP)

• Translational Science Award (TSA)
• Health Disparity Research Award (HDRA)
• Data Science Award (DSA)

Pre-Application (LOI): August 4, 2022

Application: August 25, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/pcrp

 

DoD FY22 Peer Reviewed Cancer Research Program (PRCRP)

• Convergent Science Cancer Consortium Development Award (CSCCDA)

Pre-Application (Letter of Intent): August 17

Application: September 7, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/prcrp

 

MIT Solve/The Bill and Melinda Gates Foundation

Description: MIT Solve, in collaboration with the Bill & Melinda Gates Foundation, seeks solutions that will offer new ways of measuring primary health care performance improvement in low- and middle-income countries. Please visit the application website

Application deadline: August 9, 2022

Link to Full Announcement: https://solve.mit.edu/challenges/performance-improvement#challenge-subnav-offset